Ryan Scott is an editor for OncLive, an MJH Life Sciences brand.
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Journal Digest: April 30
Daily Derm Times: April 29, 2025
Understanding the Role of OX40 in Next-Generation Eczema Therapies
How Does Psoriasis Influence Sun Tanning Addiction?